Why Is Humana Stock Dropping in 2026? Humana’s Quarterly Loss and Earnings Forecast Explained
Key Takeaways
- Financial Results: Humana reported an adjusted quarterly loss of $3.96 per share, slightly better than analyst fears but still reflecting a massive year-over-year decline.
- The “Star Ratings” Cliff: The biggest hit to 2026 earnings is a projected $3.5 billion revenue headwind due to lower Medicare Advantage Star Ratings.
- Profitability Squeeze: 2026 earnings per share (EPS) are forecasted at approximately $9.00, a sharp drop from $17.14 in 2025.
- Strategic Market Exits: To stabilize finances, Humana is exiting 194 counties and cutting certain “extra” benefits like over-the-counter (OTC) allowances.
- Comparative Outlook: While UnitedHealth shows resilience through diversification (Optum), Humana’s heavy reliance on Medicare Advantage makes it highly vulnerable to regulatory shifts.
Introduction: Understanding Humana’s Financial Troubles
If you follow the health insurance industry or own Humana stock, you’ve likely noticed troubling headlines recently. On February 11, 2026, Humana officially confirmed the scale of its financial challenges, reporting a significant quarterly loss and providing a sober 2026 outlook. For investors, Medicare Advantage members, and industry watchers, this raises critical questions: What caused this decline? Why is the stock dropping? What does this signal about the company’s long-term direction?
The answer lies in a “perfect storm” of rising medical costs and a catastrophic drop in quality-based government bonuses. Humana, one of America’s largest health insurers, is struggling with a fundamental problem: medical expenses are rising faster than the government is willing to pay. Unlike its competitor, UnitedHealth Group, Humana lacks the massive diversification needed to absorb these shocks. This explains why Humana’s 2026 outlook is considerably darker than many anticipated.